{
  "id": 3006724,
  "title": "Scinai reports H1 2026 results, announces U.S. customer expansion",
  "url": "https://urgent.news/2026/08/24/scinai-reports-h1-2026-results-announces-u-s-customer-expansion",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-24T11:24:35.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/scinai-reports-h1-2026-results-announces-us-customer-expansion-93CH-4873277"
  },
  "original_language": "en",
  "account": "Jerusalem-based Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) unveiled its H1 2026 financial results, announcing a noteworthy expansion of its clinical manufacturing program in the United States. For the six months ending June 30, 2026, the company reported revenues of $949,000, an increase from $773,000 in the same period of 2025. This growth was primarily driven by revenues from acquired Yavne operations. However, the company experienced a gross loss of approximately $2.4 million, compared to $1.3 million in the previous half-year, reflecting the expanded cost base post-acquisition. Scinai's net income for H1 2026 came in at approximately $1.6 million, a stark contrast to a net loss of about $4.1 million in the same period last year. The significant $6.4 million bargain purchase gain associated with the acquisition of Recipharm Israel, without representing operational income or cash flow, played a pivotal role in this turnaround. Operating loss narrowed to approximately $4.6 million, down from $3.8 million in the first half of 2025. Net cash used in operating activities amounted to around $3.9 million, up from $2.6 million in the previous period. As of June 30, 2026, Scinai had cash, cash equivalents, and restricted cash totaling approximately $2.9 million, with shareholders’ equity standing at about $11.7 million. The company currently boasts committed customer orders valued at $3.1 million as of August 16, 2026, with around $2.1 million already invoiced. Additionally, Scinai secured approximately $650,000 in cash payments and advances for its expanded U.S. program, aimed at supporting an investigational drug product towards U.S. IND submission and Phase III clinical development, although the definitive agreement remains under negotiation. An investor webinar is scheduled to take place on August 26, 2026, at 11:00 a.m. EDT.",
  "summary": null,
  "key_points": [
    "Scinai H1 2026 revenues rise to $949,000 from $773,000 in 2025",
    "Company reports $2.4 million gross loss, $1.6 million net income",
    "Scinai secures $650,000 in cash payments for U.S. program expansion"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}